Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современные тенденции в лечении бронхиальной астмы
Курбачева О.М., Исакова И.И. Современные тенденции в лечении бронхиальной астмы. Consilium Medicum. 2019; 21 (3): 41–44. DOI: 10.26442/20751753.2019.3.190182
________________________________________________
Kurbacheva O.M., Isakova I.I. Current trends in the treatment of bronchial asthma. Consilium Medicum. 2019; 21 (3): 41–44. DOI: 10.26442/20751753.2019.3.190182
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Бронхиальная астма (БА) является широко распространенным заболеванием дыхательной системы, оказывает значительное влияние на качество жизни пациентов. Основными целями лечения БА являются достижения контроля над симптомами, предупреждение обострений и профилактика развития осложнений. В статье рассмотрены подходы к ведению больных тяжелой БА, использование моноклональных антител в лечении БА.
Ключевые слова: бронхиальная астма, воспаление, моноклональные антитела.
Ключевые слова: бронхиальная астма, воспаление, моноклональные антитела.
________________________________________________
Bronchial asthma is a widespread disease of the respiratory system, has a significant impact on the quality of life of patients. The main objectives of the treatment of asthma is to achieve symptom control, prevent exacerbations and prevent the development of complications. The article describes approaches to the management of patients with severe asthma, the use of monoclonal antibodies in the treatment of asthma.
Key words: bronchial asthma, inflammation, monoclonal antibodies.
Key words: bronchial asthma, inflammation, monoclonal antibodies.
Полный текст
Список литературы
1. Global Strategy for Asthma Management and Prevention. Revised 2018. www.ginasthma.com
2. Сhuchalin AG, Khaltaev N, Antonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963–74.
3. Bousqet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control and exacerbitions: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926–38.
4. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2013.
[Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu bronkhial'noi astmy. 2013 (in Russian).]
5. Cazzola M, Page CP, Rogliani P, Matera MG. b2-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690–6.
6. Powell H, Cibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223–5.
7. Powell H, Cibson P. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (reviev). Cochrane Database Syst Rev 2003; 4: 223–5.
8. Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and plase in therapy. Ther Advanc Chronic Dis 2010; 2: 47–58. DOI: 10.1177/2040622310383343
9. Stephenson L. Monoclonal Antibody Therapy for Asthma. Clin Pulm Med 2017; 24: 250–7.
10. Инструкция по применению лекарственного препарата для медицинского применения Ксолар (ЛСР-000082 от 29.05.2007).
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Ksolar (LSR-000082 ot 29.05.2007) (in Russian).]
11. Alhossan A, Lee CS, MacDonald K et al. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. Allergy Clin Immunol Pract 2017; 5: 1362–70.
12. Corren J, Kavati A, Ortiz B et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy Asthma Proc 2017; 38: 250–63.
13. Инструкция по медицинскому применению препарата Синкейро (реслизумаб).
[Instruktsiia po meditsinskomu primeneniiu preparata Sinkeiro (reslizumab) (in Russian).]
14. Ortega HG, Yansey SW, Mayer B et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549–56.
15. Инструкция по применению препарата Нукала. Рег. №ЛП-004794.
[Instruktsiia po primeneniiu preparata Nukala. Reg. №LP-004794 (in Russian).]
16. Bel EH, Wenzel SE, Thompson PJ et al. NEJM 2014; 371 (13): 1189–97.
17. Domingo C. Overlapping Effects of Monoclonal Antibodies for Severe Asthma. Drugs 2017. DOI 10.1007/s40265-017-0810-5
2. Сhuchalin AG, Khaltaev N, Antonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963–74.
3. Bousqet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control and exacerbitions: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926–38.
4. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2013.
[Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu bronkhial'noi astmy. 2013 (in Russian).]
5. Cazzola M, Page CP, Rogliani P, Matera MG. b2-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690–6.
6. Powell H, Cibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223–5.
7. Powell H, Cibson P. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (reviev). Cochrane Database Syst Rev 2003; 4: 223–5.
8. Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and plase in therapy. Ther Advanc Chronic Dis 2010; 2: 47–58. DOI: 10.1177/2040622310383343
9. Stephenson L. Monoclonal Antibody Therapy for Asthma. Clin Pulm Med 2017; 24: 250–7.
10. Инструкция по применению лекарственного препарата для медицинского применения Ксолар (ЛСР-000082 от 29.05.2007).
[Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Ksolar (LSR-000082 ot 29.05.2007) (in Russian).]
11. Alhossan A, Lee CS, MacDonald K et al. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. Allergy Clin Immunol Pract 2017; 5: 1362–70.
12. Corren J, Kavati A, Ortiz B et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy Asthma Proc 2017; 38: 250–63.
13. Инструкция по медицинскому применению препарата Синкейро (реслизумаб).
[Instruktsiia po meditsinskomu primeneniiu preparata Sinkeiro (reslizumab) (in Russian).]
14. Ortega HG, Yansey SW, Mayer B et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549–56.
15. Инструкция по применению препарата Нукала. Рег. №ЛП-004794.
[Instruktsiia po primeneniiu preparata Nukala. Reg. №LP-004794 (in Russian).]
16. Bel EH, Wenzel SE, Thompson PJ et al. NEJM 2014; 371 (13): 1189–97.
17. Domingo C. Overlapping Effects of Monoclonal Antibodies for Severe Asthma. Drugs 2017. DOI 10.1007/s40265-017-0810-5
________________________________________________
1. Global Strategy for Asthma Management and Prevention. Revised 2018. www.ginasthma.com
2. Сhuchalin AG, Khaltaev N, Antonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963–74.
3. Bousqet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control and exacerbitions: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926–38.
4. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniiu bronkhial'noi astmy. 2013 (in Russian).
5. Cazzola M, Page CP, Rogliani P, Matera MG. b2-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690–6.
6. Powell H, Cibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223–5.
7. Powell H, Cibson P. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children (reviev). Cochrane Database Syst Rev 2003; 4: 223–5.
8. Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and plase in therapy. Ther Advanc Chronic Dis 2010; 2: 47–58. DOI: 10.1177/2040622310383343
9. Stephenson L. Monoclonal Antibody Therapy for Asthma. Clin Pulm Med 2017; 24: 250–7.
10. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Ksolar (LSR-000082 ot 29.05.2007) (in Russian).
11. Alhossan A, Lee CS, MacDonald K et al. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. Allergy Clin Immunol Pract 2017; 5: 1362–70.
12. Corren J, Kavati A, Ortiz B et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy Asthma Proc 2017; 38: 250–63.
13. Instruktsiia po meditsinskomu primeneniiu preparata Sinkeiro (reslizumab) (in Russian).
14. Ortega HG, Yansey SW, Mayer B et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549–56.
15. Instruktsiia po primeneniiu preparata Nukala. Reg. №LP-004794 (in Russian).
16. Bel EH, Wenzel SE, Thompson PJ et al. NEJM 2014; 371 (13): 1189–97.
17. Domingo C. Overlapping Effects of Monoclonal Antibodies for Severe Asthma. Drugs 2017. DOI 10.1007/s40265-017-0810-5
Авторы
О.М.Курбачева*, И.И.Исакова
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*kurbacheva@gmail.com
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*kurbacheva@gmail.com
________________________________________________
Oksana M. Kurbacheva*, Irina I. Isakova
National Research Center – Institute of Immunology, Moscow, Russia
National Research Center – Institute of Immunology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.